Clinical trial
Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia
To assess the efficacy of NewGam in correcting the platelet count.
| Category | Value |
|---|---|
| Study start date | 2011-04-12 |